Liquidia (NASDAQ:LQDA) CAO Sells $413,489.21 in Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 11,047 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $413,489.21. Following the sale, the chief accounting officer owned 156,700 shares in the company, valued at approximately $5,865,281. This trade represents a 6.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Dana Boyle also recently made the following trade(s):

• On Monday, December 1st, Dana Boyle sold 303 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total value of $9,753.57.
• On Monday, October 27th, Dana Boyle sold 1,073 shares of Liquidia stock. The shares were sold at an average price of $22.93, for a total value of $24,603.89.

Liquidia Price Performance

Shares of LQDA traded up $1.49 during midday trading on Tuesday, reaching $38.09. The stock had a trading volume of 2,055,159 shares, compared to its average volume of 2,814,845. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The company has a market capitalization of $3.31 billion, a price-to-earnings ratio of -26.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48. The company’s 50-day moving average is $31.94 and its 200 day moving average is $25.40. Liquidia Corporation has a 12-month low of $11.26 and a 12-month high of $39.29.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. The company had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.Liquidia’s quarterly revenue was up 1106.7% on a year-over-year basis. On average, equities analysts predict that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently made changes to their positions in LQDA. NewEdge Advisors LLC purchased a new stake in Liquidia in the second quarter worth $25,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Liquidia in the 3rd quarter worth about $30,000. FNY Investment Advisers LLC bought a new stake in shares of Liquidia during the 3rd quarter valued at about $34,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Liquidia by 24.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock valued at $77,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after buying an additional 4,927 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on LQDA shares. Jefferies Financial Group lifted their target price on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday. Wells Fargo & Company started coverage on Liquidia in a report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price objective on the stock. Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday. Needham & Company LLC raised their price target on Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, HC Wainwright boosted their price objective on Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined 18.1% to 10,709,682 shares as of Dec. 31 (about 17.6% of shares were sold short) and the days-to-cover was ~11.6. Fewer active shorts can reduce downside pressure and may have contributed to the stock moving higher. (Market data entry)
• Neutral Sentiment: January short-interest data shows 0 shares as of Jan. 12 — this is almost certainly a reporting or data glitch rather than a real liquidation of all short positions. Investors should monitor the next short-interest report for a corrected figure. (Market data entry)
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average $37.43 (≈$2.49M); his stake decreased ~6.03%. This large insider sale may be seen as a negative signal by some investors. SEC Filing
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 (≈$1.38M); his holding fell ~9.52%. SEC Filing
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 (≈$1.02M); his holding fell ~4.50%. SEC Filing
• Negative Sentiment: Other insiders (including Rajeev Saggar, Jason Adair, Scott Moomaw, Sarah Krepp, CAO Dana Boyle) also executed sales on Jan. 12 at ~$37.43 per share, each reducing positions between ~6–11.7%. These combined sales represent significant insider liquidity taken at current prices. Rajeev Saggar SEC Filing Dana Boyle SEC Filing Jason Adair SEC Filing Scott Moomaw SEC Filing Sarah Krepp SEC Filing

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).